drugset / Trial / NCT00847860
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
Phase 4
Completed
200 enrolled
Peking University First Hospital
Zhejiang Otsuka Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-05
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Subject | Cilostazol | Small molecule | 100 mg | — |